Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: TransKingdom RNA interference therapeutics - Adhera Therapeutics

Next Previous
Drug Profile

Research programme: TransKingdom RNA interference therapeutics - Adhera Therapeutics

Alternative Names: CEQ 400; CEQ 600; CEQ 700; CEQ-501; CEQ-626; CEQ608; CEQ609; CEQ621; CEQ631; CEQ632; tk RNAi; tkRNAi therapeutic targeting beta-catenin (CTNNB1) - Adhera Therapeutics; TransKingdom RNA interference

Latest Information Update: 03 May 2019

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cequent Pharmaceuticals
  • Developer Adhera Therapeutics
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial adenomatous polyposis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Human papillomavirus infections; Inflammatory bowel diseases

Most Recent Events

  • 16 Apr 2019 Discontinued - Preclinical for Inflammatory bowel diseases in USA (PO)
  • 16 Apr 2019 Discontinued for Human papillomavirus infections in USA (PO)
  • 28 May 2018 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top